(American Journal of Pathology. 2002;160:1503-1506.)
© 2002 American Society for Investigative Pathology
PolyA Deletions in Hereditary Nonpolyposis Colorectal Cancer
Mutations Before a Gatekeeper
Kyoung-Mee Kim*,
Reijo Salovaara
,
Jukka-Pekka Mecklin
,
Heikki J. Järvinen
,
Lauri A. Aaltonen¶ and
Darryl Shibata*
From the Department of Pathology,* Norris Cancer Center,University of Southern California School of Medicine, Los Angeles,California; the Departments of Pathology and MedicalGenetics,
Haartman Institute, Helsinki,Finland; Jyvaskyla Central Hospital,
Jyvaskyla, Finland; the Second Department ofSurgery,
Helsinki University Central Hospital,Helsinki, Finland; and the Department of MedicalGenetics,¶ Haartman Institute, University ofHelsinki, Helsinki, Finland
 |
Abstract
|
|---|
Microsatellite instability (MSI) secondary to loss of DNA mismatch
repair (MMR) is present in adenomas and colorectal carcinomas from
individuals with hereditary nonpolyposis colorectal cancer (HNPCC). To
better characterize when MMR loss occurs during HNPCC
progression, the extent of deletions in noncoding polyA
sequences were compared between 6 adenomas (all
1.0 cm in size) and
10 cancers. Numbers of deleted bases reflect time since loss of MMR
because polyA deletions are stepwise. Adenoma deletions were nearly the
same (85%) as the cancers with sum total deletions at four different
polyA loci of -32.7 bases in adenomas and -38.4 bases in cancers.
Intervals between negative clinical examinations and tumor removal
(average of 2.1 years) were known for six tumors. There were no
significant differences in the extent of deletions in tumors removed
under clinical surveillance (-34.8 bases) versus tumors
removed without prior negative examinations (-36.5 bases). These
findings illustrate that MSI is extensive in both small
adenomas, and tumors which appear after negative clinical
examinations, consistent with an early loss of MMR in
HNPCC, even before a gatekeeper mutation.
Germline mutations in mismatch
repair (MMR) loci are present in individuals with HNPCC.1
Inactivation of the normal allele, typically from loss of
heterozygosity,2
results in MMR deficiency and elevated
mutation rates.1
Mutation rates in simple repeat sequences
or microsatellite (MS) loci are increased approximately 100-fold in
MMR-deficient cell lines3,4
and widespread microsatellite
instability (MSI) is present in hereditary nonpolyposis colorectal
cancer (HNPCC) tumors.5
Most MS loci are noncoding and selection for these mutations is
unlikely. Proportions of altered MS loci have been useful for
classification of tumors as either with low or high MSI.6
High MSI (MSI-H) is strongly associated with loss of MMR.6
Comparisons between tumor and normal alleles of long polyA repeats are
sensitive indicators of MSI because most alterations are
deletions.7
Deletions occur sequentially (stepwise) with
loss of a single or a few bases at a time.3,7-9
Therefore, polyA deletions not only indicate loss of MMR but their
extent also provides information on the time since loss of
MMR.10
The MSI of HNPCC adenomas suggests MMR loss occurs early in tumor
progression.11-13
In theory, MMR loss could even precede
a gatekeeper mutation because phenotypically normal cells may be
MMR-deficient.14
It is possible to infer the past from the
extent of MS mutations or drift from germline for individual MS loci.
Patterns of MS mutations in CA repeat dinucleotide MS loci
estimate loss of MMR occurs on average approximately 6.3 years before
tumor removal (5.5 years for adenomas and 6.6 years for cancers) and
can precede a gatekeeper mutation.15
To further
characterize the timing of MMR loss during progression, the extent of
deletions at four polyA loci were compared between HNPCC adenomas and
cancers. If loss of MMR occurs very early and precedes a gatekeeper
mutation, then the extent of polyA deletions should be similar between
adenomas and cancers, regardless of prior clinical surveillance.
 |
Materials and Methods
|
|---|
DNA was extracted10
from formalin-fixed,
paraffin-embedded tumor sections of 6 adenomas and 10 carcinomas from
11 Finnish HNPCC patients (Table 1)
.
Clinical information was obtained from patient charts. Surveillance
intervals are defined as the time between a negative clinical
examination (colonoscopy or prior surgery) and removal of a new tumor.
Normal DNA was free of tumor and tumor regions were microdissected to
obtain greater than 60% of tumor cells. Germline MLH1 or MSH2
mutations were confirmed by sequencing. The t-test
(two-tail) was used to determine the significance between means.
PolyA deletions were measured by comparing germline and tumor
sizes.10
Briefly, four polyA repeat loci were examined
(BAT20, BAT25, BAT26, and BAT40). Lengths of mononucleotide repeats
were estimated by comparing the most intense polymerase chain reaction
(PCR) product band between tumor and normal DNA after electrophoresis
on 6% sequencing gels, incorporating
[33P]-dCTP (NEN Research Products, Boston, MA)
with 35 to 38 PCR cycles. In some cases, to better distinguish between
tumor and contaminating normal alleles, tumor DNA was diluted before
PCR to avoid overlapping stutter bands.
 |
Results
|
|---|
Somatic deletions were present in all four polyA loci (BAT20,
BAT25, BAT26, and BAT40) in the HNPCC adenomas and cancers (Figure 1
and Table 1
). The sum of deletions over
the four polyA loci ranged from -26 to -49 bases with overlap between
adenomas and cancers (Figure 2)
. Adenomas
had 85% of the deletions observed in the cancers (average of -32.7
versus -38.4 bases). There was a slight trend for larger
deletions in larger adenomas, but among cancers, fewer deletions were
present in higher stage cancers (Figure 3)
.

View larger version (160K):
[in this window]
[in a new window]
|
Figure 1. Examples of BAT26 deletions in adenomas
(A) and carcinomas
(T) from three HNPCC
individuals. PolyA repeat deletions are estimated by counting the
differences between the densest band (indicated
by triangles) from normal
(N) and tumor DNA.
|
|

View larger version (45K):
[in this window]
[in a new window]
|
Figure 2. Summary of polyA deletions in adenomas and carcinomas. Average
deletions for all tumors were -8.7 bases for BAT20, -6.3 bases for
BAT25, -10.8 bases for BAT26, and -10.4 bases for BAT40. Average
total deletions were -32.7 bases for the adenomas
versus -38.4 bases for the cancers.
|
|
Some of the HNPCC patients were under surveillance with six known
intervals (average of 2.1 years) between tumor removal and a prior
negative clinical examination (Table 1)
. There was a slight trend for
fewer deletions in tumors with longer surveillance intervals (Figure 4)
. Surveillance did not significantly
reduce mutations in the polyA sequences because tumors removed after
negative clinical examinations had average deletions of -34.8 bases
versus -36.5 bases (P = 0.66) for
tumors removed without prior surveillance.

View larger version (16K):
[in this window]
[in a new window]
|
Figure 4. Few differences in total polyA deletions regardless of interval after a
negative examination, or whether under clinical surveillance.
|
|
 |
Discussion
|
|---|
Loss or inactivation of the functional MMR allele in HNPCC marks a
"second-hit" and starts the accumulation of mutations in MS loci.
Frame-shift mutations characteristic of MMR deficiencies are found in a
number of tumor suppressor loci such as TGFBRII and BAX in HNPCC
tumors,16,17
suggesting loss of MMR precedes these
mutations. However, designating exactly when MMR loss occurs during
progression is difficult because "time" is typically based on
morphological and frequency criteria. Mutations present in both
adenomas and cancers are "early" mutations whereas "late"
mutations are found more frequently in cancers.18
The
extensive MSI observed in HNPCC adenomas and carcinomas suggest loss of
MMR occurs early in progression.3,11-13
Determining when a mutation occurs may be confounded by the requirement
that only mutations accompanied by a gatekeeper mutation are
detectable. A gatekeeper mutation1
is defined here as the
first mutation that allows for visible clonal expansion. Progenitors
with mutations other than gatekeeper mutations are "invisible".
Such scenarios are illustrated in Figure 5
using an "imaginary" observer with
the omniscient ability to see a MMR "clock" which may start whether
or not it is accompanied by a tumor. Imaginary and real observers will
agree on late MMR loss because tumors with and without MMR deficiency
can be sampled. In contrast, only the imaginary observer can see the
early MMR loss and accumulation of MS mutations that precede a
gatekeeper mutation because a real observer will see nothing. However,
a real observer may be just as knowledgeable because the clock can be
examined when the tumor is removed. Assuming an ability to recognize
and interpret this clock, a real observer can infer when it started.

View larger version (64K):
[in this window]
[in a new window]
|
Figure 5. Possible MMR loss scenarios. Loss of MMR can only be physically
detected after a gatekeeper mutation because otherwise no tumor is
present. However, an "imaginary" omniscient observer can watch for
the accumulation of MS mutations (depicted here
as the shaded portion of a MMR clock)
whether or not a visible tumor is present. When MMR loss precedes a
gatekeeper mutation, mutations accumulate in clinically occult
progenitors. If MMR loss occurs very early relative to a gatekeeper
mutation, both adenomas and cancers will have extensive MSI. Tumors
that appear shortly after negative clinical examinations will also have
extensive MSI because most mutations accumulate in occult progenitors.
A real observer who can only examine tumors may infer when loss of MMR
occurs by realizing the clock-like nature of polyA deletions.
|
|
PolyA deletions were similar between HNPCC adenomas and cancers, and
between tumors regardless of clinical surveillance. The scenario most
consistent with these observations is MMR loss that greatly precedes a
gatekeeper mutation. With this scenario (Figure 5)
, adenomas have as
nearly as many polyA deletions as cancers because most MS mutations
occur before a gatekeeper mutation. Tumors arising with or without
prior negative clinical examinations would have similar numbers of
deletions because most deletions accumulate in occult progenitors.
With early MMR loss, the final extent of MSI in HNPCC adenomas or
cancers would not be surprising for an imaginary omnipresent observer
(Figure 5)
, but a real observer might conclude that MMR loss is
associated with catastrophic MSI because intermediate MSI states are
seldom observed.19,20
A real observer may also question
whether polyA deletions reflect times since loss of MMR because
proliferation kinetics vary during progression. However, a key feature
of very early MMR loss is that phenotypic differences between adenomas
or cancers would have relatively minor effects on the polyA clock
because most of their histories are written in normal colon. Most MS
mutations accumulate unobserved in phenotypically normal progenitors
that are likely to have similar proliferation rates. In addition, polyA
repeat sequences exhibit molecular clock properties in many different
MMR deficient cells including normal murine intestines and human cancer
cell lines.3,7-10
Total deletions are not precise time
measures because mutations are stochastic10
and confidence
intervals (not calculated here) would be expected to be large.
The polyA repeat tumor clock analysis also concurs with a quantitative
analysis of CA-dinucleotide repeats,15
with similar
and small differences between adenomas and cancers, with or without
surveillance (Table 2)
. Although the
current polyA sequence analysis is not formally quantitative, both CA-
and polyA-repeat mutation patterns support the conclusion that loss of
MMR often precedes a gatekeeper mutation. The mutation spectrum of
APC is also consistent with MMR loss preceding APC mutation in
most MSI-H cancers.21
APC mutations likely lag BAT polyA
repeat deletions because APC coding regions lack long repeats
(
A8) and mutation rates are markedly lower for
shorter polyA repeats.9
The start of progression has been usually defined as a visible change
in phenotype.22
However, the start of genetic progression
(the accumulation of mutations) does not need to coincide with visible
HNPCC tumor progression because MMR deficient tissues may accumulate MS
mutations and remain phenotypically normal.14,23
Many or
most mutations may potentially accumulate before the onset of visible
neoplasia. Loss of MMR may not even mark the start of genetic
progression because some mutations found in MSI-H tumors lack features
characteristic of MMR loss.21
Further systematic studies
of tumor mutations may help better characterize the frequencies and
lengths of occult genetic progression periods.
 |
Acknowledgements
|
|---|
We thank Sylvia I. Lambrechts and Sarka Cernosek for technical
assistance.
 |
Footnotes
|
|---|
Address reprint requests to Darryl Shibata, M.D., Department of Pathology, University of Southern California School of Medicine, 1200 N. State St., Unit I, Room 2428, Los Angeles, CA 90033. E-mail:
dshibata{at}hsc.usc.edu
Supported in part by a postdoctoral fellowship to K.-M. Kim from the Korea Science and Engineering Foundation.
Accepted for publication January 4, 2002.
 |
References
|
|---|
-
Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170[Medline]
-
Hemminki A, Peltomaki P, Mecklin JP, Jarvinen H, Salovaara R, Nystrom-Lahti M, de la Chapelle A, Aaltonen LA: Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nat Genet 1994, 8:405-410[Medline]
-
Shibata D, Peinado MA, Ionov Y, Malkhosyan S, Perucho M: Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet 1994, 6:273-281[Medline]
-
Bhattacharyya NP, Skandalis A, Ganesh A, Groden J, Meuth M: Mutator phenotypes in human colorectal carcinoma cell lines. Proc Natl Acad Sci USA 1994, 91:6319-6323[Abstract/Free Full Text]
-
Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR, Petersen GM, Kinzler KW, Vogelstein B, de la Chapelle A: Clues to the pathogenesis of familial colorectal cancer. Science 1993, 260:812-816[Abstract/Free Full Text]
-
Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S: A National Cancer Institute Workshop on Microsatellite Instability for Cancer Detection and Familial Predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58:5248-5257[Abstract/Free Full Text]
-
Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993, 363:558-561[Medline]
-
Percesepe A, Pedroni M, Sala E, Menigatti M, Borghi F, Losi L, Viel A, Genuardi M, Benatti P, Roncucci L, Peltomaki P, Ponz de Leon M: Genomic instability and target gene mutations in colon cancers with different degrees of allelic shifts. Genes Chromosomes Cancer 2000, 27:424-429[Medline]
-
Tran HT, Keen JD, Kricker M, Resnick MA, Gordenin DA: Hypermutability of homonucleotide runs in mismatch repair and DNA polymerase proofreading yeast mutants. Mol Cell Biol 1997, 17:2859-2865[Abstract]
-
Blake C, Tsao J-L, Wu A, Shibata D: Stepwise deletions of polyA sequences in mismatch repair deficient colorectal cancers. Am J Pathol 2001, 158:1867-1870[Abstract/Free Full Text]
-
Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, Green JS, Lynch HT, Watson P, Tallqvist G, Juhola M, Sistonen P, Hamilton SR, Kinzler KW, Vogelstein B, de la Chapelle A: Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 1994, 54:1645-1648[Abstract/Free Full Text]
-
Iino H, Simms L, Young J, Arnold J, Winship IM, Webb SI, Furlong KL, Leggett B, Jass JR: DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer. Gut 2000, 47:37-42[Abstract/Free Full Text]
-
Loeb LA: A mutator phenotype in cancer. Cancer Res 2001, 61:3230-3239[Abstract/Free Full Text]
-
Parsons R, Li GM, Longley M, Modrich P, Liu B, Berk T, Hamilton SR, Kinzler KW, Vogelstein B: Mismatch repair deficiency in phenotypically normal human cells. Science 1995, 268:738-740[Abstract/Free Full Text]
-
Tsao JL, Yatabe Y, Salovaara R, Jarvinen HJ, Mecklin JP, Aaltonen LA, Tavare S, Shibata D: Genetic reconstruction of individual colorectal tumor histories. Proc Natl Acad Sci USA 2000, 97:1236-1241[Abstract/Free Full Text]
-
Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338[Abstract/Free Full Text]
-
Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M: Somatic frame-shift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997, 275:967-969[Abstract/Free Full Text]
-
Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767[Medline]
-
Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 1993, 260:816-819[Abstract/Free Full Text]
-
Thibodeau SN, French AJ, Cunningham JM, Tester D, Burgart LJ, Roche PC, McDonnell SK, Schaid DJ, Vockley CW, Michels VV, Farr GH, Jr, OConnell MJ: Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res 1998, 58:1713-1718[Abstract/Free Full Text]
-
Huang J, Papadopoulos N, McKinley AJ, Farrington SM, Curtis LJ, Wyllie AH, Zheng S, Willson JK, Markowitz SD, Morin P, Kinzler KW, Vogelstein B, Dunlop MG: APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci USA 1996, 93:9049-9054[Abstract/Free Full Text]
-
Nowell PC: The clonal evolution of tumor cell populations. Science 1976, 194:23-28[Abstract/Free Full Text]
-
Vilkki S, Tsao JL, Loukola A, Poyhonen M, Vierimaa O, Herva R, Aaltonen LA, Shibata D: Extensive somatic microsatellite mutations in normal human tissue. Cancer Res 2001, 61:4541-4544[Abstract/Free Full Text]
Related articles in Am J Pathol:
- This Month in AJP
Am J Pathol 2002 160: 1195-1196.
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
H. Alazzouzi, E. Domingo, S. Gonzalez, I. Blanco, M. Armengol, E. Espin, A. Plaja, S. Schwartz, G. Capella, and S. Schwartz Jr
Low levels of microsatellite instability characterize MLH1 and MSH2 HNPCC carriers before tumor diagnosis
Hum. Mol. Genet.,
January 15, 2005;
14(2):
235 - 239.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Calabrese, J.-L. Tsao, Y. Yatabe, R. Salovaara, J.-P. Mecklin, H. J. Jarvinen, L. A. Aaltonen, S. Tavare, and D. Shibata
Colorectal Pretumor Progression Before and After Loss of DNA Mismatch Repair
Am. J. Pathol.,
April 1, 2004;
164(4):
1447 - 1453.
[Abstract]
[Full Text]
[PDF]
|
 |
|